User profiles for Brian R. Ott

Brian R Ott

Brown University
Verified email at brown.edu
Cited by 19677

A controlled trial of tacrine in Alzheimer's disease

…, S Madan, R Hanning, W Martinez, R Stone… - Jama, 1992 - jamanetwork.com
Objective. —To compare efficacy and safety of tacrine hydrochloride with placebo in
patients with probable Alzheimer's disease. Design. —A 12-week, double-blind, placebo-controlled, …

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the …

…, F Mach, BR Ott, E Kanevsky, AL Pineda, R Somaratne… - The Lancet, 2017 - thelancet.com
Background LDL cholesterol is a well established risk factor for atherosclerotic cardiovascular
disease. How much one should or safely can lower this risk factor remains debated. We …

[HTML][HTML] Cognitive function in a randomized trial of evolocumab

…, N Honarpour, SM Wasserman, BR Ott - … England Journal of …, 2017 - Mass Medical Soc
Background Findings from clinical trials of proprotein convertase subtilisin–kexin type 9 (PCSK9)
inhibitors have led to concern that these drugs or the low levels of low-density …

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial

ER Peskind, SG Potkin, N Pomara, BR Ott… - The American Journal of …, 2006 - Elsevier
Objective The objective of this study was to compare the efficacy and safety of the moderate-affinity,
uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo …

Patient versus informant perspectives of quality of life in mild cognitive impairment and Alzheimer's disease

RE Ready, BR Ott, J Grace - International journal of geriatric …, 2004 - Wiley Online Library
Background Prior studies on Quality of Life (QOL) in Alzheimer's disease (AD) have rarely
included control participants, or participants with very mild levels of cognitive impairment. …

[HTML][HTML] Quality of life measures for dementia

RE Ready, BR Ott - Health and quality of life outcomes, 2003 - Springer
Over the past 10 years, several instruments developed specifically for the assessment of
Quality of Life (QOL) in dementia have been introduced. The goal of the current review is to …

Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional–executive network function in Alzheimer's disease

…, S Asthana, D Bandy, R Bartha… - Proceedings of the …, 2010 - National Acad Sciences
The ε4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for
Alzheimer’s disease (AD), but limited work has suggested that APOE genotype may modulate …

Impaired awareness of deficits in Alzheimer disease

BR Ott, G Lafleche, WM Whelihan… - Alzheimer Disease & …, 1996 - journals.lww.com
This study examined the relation between awareness of memory and functional decline and
cognitive function in patients with Alzheimer disease (AD). Twentysix patients with early AD …

[HTML][HTML] Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials

BR Ott, LA Daiello, IJ Dahabreh, BA Springate… - Journal of general …, 2015 - Springer
BACKGROUND In 2012, the United States Food and Drug Administration (FDA) issued a
warning regarding potential adverse effects of HMG-CoA reductase inhibitors (statins) on …

The older adult driver with cognitive impairment:“It's a very frustrating life”

DB Carr, BR Ott - Jama, 2010 - jamanetwork.com
Although automobiles remain the transportation of choice for many older adults, late-life
cognitive impairment and dementia often impair the ability to drive safely. However, there is no …